Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 398

Similar articles for PubMed (Select 22282894)


Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.

Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, Markus HS, Bath MW, Bath PM; Acute Antiplatelet Stroke Trialists Collaboration.

Stroke. 2012 Apr;43(4):1058-66. doi: 10.1161/STROKEAHA.111.637686. Epub 2012 Jan 26. Review.


Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.

Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310. Review.


Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.

Leonardi-Bee J, Bath PM, Bousser MG, Davalos A, Diener HC, Guiraud-Chaumeil B, Sivenius J, Yatsu F, Dewey ME; Dipyridamole in Stroke Collaboration (DISC).

Stroke. 2005 Jan;36(1):162-8. Epub 2004 Nov 29. Review.


Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis.

Wong KS, Wang Y, Leng X, Mao C, Tang J, Bath PM, Markus HS, Gorelick PB, Liu L, Lin W, Wang Y.

Circulation. 2013 Oct 8;128(15):1656-66. doi: 10.1161/CIRCULATIONAHA.113.003187. Epub 2013 Sep 12. Review.


Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.

Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B.

Ann Intern Med. 2013 Oct 1;159(7):463-70. doi: 10.7326/0003-4819-159-7-201310010-00006. Review.


Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.

Biller J.

J Neurol Sci. 2009 Sep 15;284(1-2):1-9. doi: 10.1016/j.jns.2009.04.001. Epub 2009 Apr 19. Review.


Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.

Bath PM, Cotton D, Martin RH, Palesch Y, Yusuf S, Sacco R, Diener HC, Estol C, Roberts R; PRoFESS Study Group.

Stroke. 2010 Apr;41(4):732-8. doi: 10.1161/STROKEAHA.109.564906. Epub 2010 Feb 24.


Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.


Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.

Geeganage C, Wilcox R, Bath PM.

BMC Med. 2010 Jun 16;8:36. doi: 10.1186/1741-7015-8-36. Review.


Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.

Diedler J, Ahmed N, Sykora M, Uyttenboogaart M, Overgaard K, Luijckx GJ, Soinne L, Ford GA, Lees KR, Wahlgren N, Ringleb P.

Stroke. 2010 Feb;41(2):288-94. doi: 10.1161/STROKEAHA.109.559724. Epub 2010 Jan 7.


Duration of dual antiplatelet therapy after implantation of drug-eluting stents.

Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K.

N Engl J Med. 2010 Apr 15;362(15):1374-82. doi: 10.1056/NEJMoa1001266. Epub 2010 Mar 15.


Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.

Sarasin FP, Gaspoz JM, Bounameaux H.

Arch Intern Med. 2000 Oct 9;160(18):2773-8.


Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events.

Bowry AD, Brookhart MA, Choudhry NK.

Am J Cardiol. 2008 Apr 1;101(7):960-6. doi: 10.1016/j.amjcard.2007.11.057. Epub 2008 Feb 11. Review.


Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.

Hankey GJ, Eikelboom JW.

Neurology. 2005 Apr 12;64(7):1117-21. Review.


Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

Reaume KT, Regal RE, Dorsch MP.

Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4. Review.


Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators.

J Am Coll Cardiol. 2007 May 15;49(19):1982-8. Epub 2007 Apr 11.


Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.

Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial.

Circulation. 2004 Sep 7;110(10):1202-8. Epub 2004 Aug 16.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk